关键词: 血清, 血浆, TGF?β1, 膀胱癌

Abstract: ［Abstract］ Objective The purpose of this study was to analyze the expression of TGF?β1， IL?6 and IL?10 in the matched serum and plasma of patients with urologic diseases， and to investigate their clinical significance. Methods The serum and plasma samples were obtained from 42 patients diagnosed bladder cancer and 30 patients diagnosed urolithiasis from July 2015 to February 2016. The expression of TGF?β1， IL?6 and IL?10 in the serum and plasma were assessed by enzyme?linked immunosorbent assay （ELISA）. Nonparametric Wilcoxon analysis was used to evaluate the differences of cytokine expression in matched serum and plasma. Kruskal?Wallis analysis was applied to evaluate the clinical significance of TGF?β1 expression in matched serum and plasma collected from patients with bladder cancer. Result The concentration of TGF?β1 in serum is higher than it in the matched plasma （P<0.0001）. However， the concentrations of IL?6 and IL?10 had no statistical significance in the matched serum group and plasma group （P>0.05）. Compared to the Urolithiasis group， the level of TGF?β1 in tumor group was significantly elevated （P<0.01）. Moreover， the level of TGF?β1 in serum was positively associated with tumor stage and grade （P<0.05）. In contrast， the level of TGF?β1 in plasma group had no statistically significance （P>0.05）. Conclusion The expression of TGF?β1 in serum， but not plasma， was positively associated with tumor grade and stage， which suggested that the serum expression of TGF?β1 might be a potential biomarker for diagnosis and surveillance in urothelial cell carcinoma of the bladder.

Key words: urothelial cell carcinoma of the bladder, TGF?β1, plasma, serum